{"componentChunkName":"component---src-pages-about-js","path":"/about","result":{"data":{"page":{"label":"About Palforzia","url":"/about","title":"About Palforzia","header":{"title":"PALFORZIA: THE FIRST AND ONLY FDA-APPROVED ORAL IMMUNOTHERAPY (OIT) FOR PEANUT ALLERGY","references":[{"title":"PALFORZIA [package insert]. Brisbane, CA: Aimmune Therapeutics, Inc."}]},"content":[{"__typename":"ContentfulHcpAboutAssemblyA"},{"__typename":"ContentfulHcpAboutAssemblyAV2","title":"Why Palforzia?","topicA":{"title":"Why Palforzia?","richContent":{"json":{"nodeType":"document","data":{},"content":[{"nodeType":"paragraph","content":[{"nodeType":"text","value":"Itâ€™s the only treatment proven in clinical trials to reduce the severity of an allergic reaction to peanut in children aged 4 through 17 years with a confirmed diagnosis of peanut allergy","marks":[],"data":{}}],"data":{}},{"nodeType":"paragraph","content":[{"nodeType":"text","value":"PALFORZIA is intended to decrease sensitivity to small amounts of peanuts that may be hidden in food by gradually increasing the amount of peanut allergen the child is exposed to each day","marks":[],"data":{}}],"data":{}}]}},"references":null}},{"__typename":"ContentfulHcpAboutAssemblyB","title":"The First and Only","header":{"title":"A precise, standardized  approach","references":null},"topicB":{"title":"A precise standardized approach","richContent":{"json":{"nodeType":"document","data":{},"content":[{"nodeType":"paragraph","content":[{"nodeType":"text","value":"Contains defined, prepackaged amounts of peanut\nprotein for standardized dosing and administration","marks":[],"data":{}}],"data":{}},{"nodeType":"paragraph","content":[{"nodeType":"text","value":"Defined formulation with key peanut allergens measured for","marks":[{"type":"bold"}],"data":{}},{"nodeType":"text","value":" ","marks":[],"data":{}},{"nodeType":"text","value":"consistent potency, profile, and stability","marks":[{"type":"bold"}],"data":{}}],"data":{}},{"nodeType":"paragraph","content":[{"nodeType":"text","value":"Consistent allergen profile based on immunogenicity to\nthe major and minor allergenic proteins found in peanuts","marks":[],"data":{}}],"data":{}}]}},"references":null},"disclaimer":{"title":"Disclaimer","richContent":{"json":{"data":{},"content":[{"data":{},"content":[{"data":{},"marks":[],"value":"*Each dose meets specifications for quantities of Ara h 1, Ara h 2, and Ara h 6, measured by immunoassay alone or in combination with high-performance liquid chromatography.","nodeType":"text"}],"nodeType":"paragraph"}],"nodeType":"document"}},"references":[{"title":"PALFORZIA [package insert]. Brisbane, CA: Aimmune Therapeutics, Inc."}]},"figure":{"localFile":{"publicURL":"/static/df9884fc4cf60965b21154f792a38008/Hand_Illustration.svg"}}},{"__typename":"ContentfulHcpAboutAssemblyC","title":"Discover more about PALFORZIA","content":[{"title":"PALFORZIA met its primary endpoint in the PALISADE trial","figure":{"localFile":{"publicURL":"/static/2ebd28e863bbe0f6409ff9df72389053/Primary-Endpoints.svg"}},"cta":{"label":"See Results","action":{"type":"ContentfulHcpPage","label":"Palisade","url":"/palisade"},"image":null,"showIcon":null}},{"title":"Take the first step toward implementing PALFORZIA in your practice","figure":{"localFile":{"publicURL":"/static/64f860005387618010e3f6e63c859bb2/Pill.svg"}},"cta":{"label":"Get Started","action":{"type":"ContentfulHcpPage","label":"Get Started","url":"/getstarted"},"image":null,"showIcon":null}},{"title":"Help patients reach maintenance treatment with clear dosing steps","figure":{"localFile":{"publicURL":"/static/a544a842f5ef9a117efd2891fc508a12/Target.svg"}},"cta":{"label":"See Dosing","action":{"type":"ContentfulHcpPage","label":"Dosing","url":"/dosing"},"image":null,"showIcon":null}}]}],"referencesHeader":{"title":"References","references":null}}},"pageContext":{"maxWidths":[1140,960,720,540],"xlDevice":1200,"lgDevice":992,"mdDevice":768,"smDevice":576}}}